Health Care & Life Sciences » Biotechnology | Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc. | Ownership

Companies that own Brainstorm Cell Therapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Sabby Capital LLC
929,725
4.5%
907,402
1.81%
06/30/2018
The Vanguard Group, Inc.
690,257
3.34%
14,200
0%
06/30/2018
JPMorgan Securities LLC (Investment Management)
130,086
0.63%
130,086
0%
06/30/2018
Renaissance Technologies LLC
115,400
0.56%
26,299
0%
06/30/2018
Geode Capital Management LLC
105,273
0.51%
19,563
0%
06/30/2018
BlackRock Fund Advisors
79,434
0.38%
3,185
0%
06/30/2018
Psagot Mutual Funds Ltd.
55,241
0.27%
16,126
0.01%
06/30/2018
Morgan Stanley Smith Barney LLC (Private Banking)
53,077
0.26%
3,877
0%
06/30/2018
Northern Trust Investments, Inc.
36,496
0.18%
2,273
0%
06/30/2018
ETF Managers Group LLC
29,052
0.14%
-1,001
0.01%
06/30/2018

About Brainstorm Cell Therapeutics

View Profile
Address
1325 Avenue of Americas
New York New Jersey 10019
United States
Employees -
Website http://www.brainstorm-cell.com
Updated 07/08/2019
Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in New York, NJ.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.